Company profile: NanoView Biosciences
1.1 - Company Overview
Company description
- Provider of proprietary products supporting research, translation and delivery of precision medicine, built on a novel platform that uniquely identifies and characterizes exosomes. Offers high-throughput, cost-effective analysis, including Leprechaun for lentivirus and exosome biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based methods.
Products and services
- High-Throughput Analysis Systems: Delivers cost-effective particle analysis that enables life science research, supporting precision medicine translation with high-throughput exosome identification and characterization
- Leprechaun: Characterizes lentivirus and exosome particles via biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based assays
- Proprietary Exosome Characterization Platform: Uniquely identifies and characterizes exosomes to support research, translation, and delivery of precision medicine with cost-effective analysis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NanoView Biosciences
Micropharma
HQ: Canada
Website
- Description: Provider of biotherapeutics, diagnostics, and devices for metabolic diseases, discovering and developing bacteria-based biotherapeutics and novel probiotic and enzymatic solutions through a unique approach from basic research to product development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micropharma company profile →
Vicebio
HQ: United Kingdom
Website
- Description: Provider of next-generation respiratory virus vaccines leveraging Molecular Clamp platform technology to stabilize viral glycoproteins in pre-fusion conformation, delivering broad protection and ready-to-use formulations. Pipeline includes bivalent RSV/hMPV (VXB-241), trivalent RSV-hMPV-PIV3, influenza A, SARS-CoV-2, and candidates for MERS, Ebola, and Nipah.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicebio company profile →
Normax Biomed
HQ: Ireland
Website
- Description: Provider of mRNA vaccine R&D and manufacturing for infectious diseases such as tuberculosis and HIV. Delivers Vax Factory, a modular solution for rapid, scalable production; leads the mRNA UCV Consortium; and runs GOAL 2050 to end TB and HIV transmission via mRNA vaccines, affordable treatments, and education, supporting the SDG for good health & well being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normax Biomed company profile →
Affinium Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research and development focused on novel anti-infective medicines, advancing FASII antibacterial programs as a new antibiotic franchise with potential for multiple products targeting the FASII pathway, supported by a broad base of long-term intellectual property.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affinium Pharmaceuticals company profile →
Mymetics
HQ: Switzerland
Website
- Description: Provider of virosome-based vaccine R&D and immunotherapies, focused on next-generation preventative vaccines for infectious diseases. Pipeline includes HIV-1/AIDS, intranasal influenza, malaria, herpes simplex virus and RSV, plus candidates for Covid-19 and COP allergy immunotherapy, and research collaborations in cancer immunotherapy. Swiss-based with a research lab in the Netherlands.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mymetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NanoView Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NanoView Biosciences
2.2 - Growth funds investing in similar companies to NanoView Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NanoView Biosciences
4.2 - Public trading comparable groups for NanoView Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →